Kodiak Sciences Inc.
KOD · XNASCIK 1468748fmd_0M6MVND5HW99R4HV98E2TKRMGQManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 14 | 22 | 19 | 38 | 107 | 217 | 268 | 206 | 126 | 182 |
| Total operating expenses | 17 | 26 | 26 | 49 | 136 | 267 | 341 | 277 | 187 | 234 |
| Operating income | (17) | (26) | (26) | (49) | (136) | (267) | (341) | (277) | (187) | (234) |
| Interest expense | 0 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | 0 | 1 | 2 | 3 | 0 | 7 | 17 | 11 | 5 |
| Other non-operating income (expense) | 0 | (1) | (5) | 0 | (0) | (0) | 1 | 0 | (1) | (0) |
| Income before taxes | (17) | (28) | (41) | (47) | (133) | (267) | (334) | (260) | (176) | (230) |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (133) | (267) | (334) | (260) | (176) | (230) |
| Net income | (17) | (28) | (41) | (47) | (133) | (267) | (334) | (260) | (176) | (230) |
| Net income to common shareholders | (17) | (28) | (41) | – | – | – | – | – | – | – |